Free Trial
→ Trump’s New Dollar revealed (From Porter & Company) (Ad)tc pixel
NASDAQ:RVPH

Reviva Pharmaceuticals Q1 2025 Earnings Report

Reviva Pharmaceuticals logo
$0.61 +0.02 (+3.19%)
As of 03:48 PM Eastern
ProfileEarnings HistoryForecast

Reviva Pharmaceuticals EPS Results

Actual EPS
-$2.60
Consensus EPS
-$4.20
Beat/Miss
Beat by +$1.60
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q1 2025
Date
5/15/2025
Time
Before Market Opens
Conference Call Date
Thursday, May 15, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Reviva Pharmaceuticals' Q1 2025 Press ReleasePress Release
(8-K)
Reviva Pharmaceuticals' Q1 2025 Quarterly reportQuarterly report
(10-Q)

Reviva Pharmaceuticals Earnings Headlines

Reviva Pharmaceuticals (NASDAQ:RVPH) and Gain Therapeutics (NASDAQ:GANX) Financial Review
June 1 at 5:25 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30813918
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of "Moderate Buy" from Brokerages
May 26, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30800560
9 days.
SpaceX is set to price on June 12 in what could be the largest IPO in history at a $1.75 trillion valuation. Before that happens, analyst Dylan Jovine says there's one small, publicly traded company that Musk's entire empire depends on - and it's still dirt cheap. Once the S-1 hits and every fund and financial journalist starts digging, this window closes. Jovine is releasing the name and ticker today.tc pixel
June 4 at 1:00 AM  |  Behind the Markets (Ad)
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/reviva-participate-fireside-chat-g-120000847.html
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296578/0/en/reviva-to-participate-in-fireside-chat-at-a-g-p-s-annual-healthcare-company-showcase.html
OTC Listing Leaves Reviva Pharmaceuticals Shares Vulnerable to Thin Trading and Volatile Price Swings
May 15, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/otc-listing-leaves-reviva-pharmaceuticals-shares-vulnerable-to-thin-trading-and-volatile-price-swings?utm_source=marketbeat.com&utm_medium=referral
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry.

Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs.

Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.

View Reviva Pharmaceuticals Profile
Earnings Tools